The polycythemia treatment market is expanding due to increased use of JAK inhibitors like ruxolitinib, phlebotomy, and enhanced diagnostic screening for myeloproliferative neoplasms such as polycythemia vera. https://www.datamintelligence.com/research-report/polycythemia-market